Ignite Creation Date:
2025-12-24 @ 9:32 PM
Ignite Modification Date:
2025-12-29 @ 1:30 PM
Study NCT ID:
NCT06331832
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2024-03-26
First Post:
2024-03-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL
Sponsor:
IGM Biosciences, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Relapsed/Refractory Non-Hodgkin Lymphomas | View |
Keywords: